Vectura Group PLC (VEC.L)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|71||2014||Non-Executive Chairman of the Board|
|51||2015||Chief Executive Officer, Executive Director|
|2018||Chief Financial Officer, Executive Director|
|2016||Executive Vice President – Oral Business|
|2017||Chief Medical Officer & Executive Vice President - Development|
- Should You Ditch GlaxoSmithKline plc And Buy Vectura Group PLC And SkyePharma PLC?
- Are Vectura Group PLC, AstraZeneca plc And Lookers PLC 'Screaming Buys'?
- Are Vectura Group PLC And Circassia Pharmaceuticals PLC Better Buys Than GlaxoSmithKline plc?
- Why Vectura Group PLC Could Be The Perfect Partner For AstraZeneca plc In Your Portfolio
- Profit From The Biotech Boom With Vectura Group PLC, Hikma Pharmaceuticals Plc And Indivior PLC